Home Blog Page 232
Illumina's HiSeq 2500
Illumina entered three separate deals with three European labs under which they will use Illumina's consumables and the HiSeq 2500 to develop and perform noninvasive prenatal testing (NIPT) in their respective nations. French lab-testing service firm Biomnis will make NIPT available in France, Italian molecular genetics lab Genoma will perform NIPT services in Italy, and the Center for Human...
Source: © kentoh - Fotolia.com
Consider this scenario: “In five or ten years, you will show up at your doctor’s office, not feeling well, with a thumb drive that contains all your important health-related information, including a copy of your entire genome. Your physician will run the disk through a sophisticated computer and, after studying the results, prescribe a treatment, maybe even a form of...
Sharon Terry is president and CEO of Genetic Alliance.
The task of finding and recruiting sufficiently large cohorts for studying genetic diseases has up to now been a needle in the haystack problem. This is rapidly changing as Sharon F. Terry, and her colleagues at Genetic Alliance are making possible aggregation of individual health information in ways and on a scale never seen before. In the process, they...
Incidental findings occur in clinical
Recent developments reveal both the beginnings of consensus, and many more unresolved issues, when it comes to “incidental” or unexpected findings uncovered during genome or exome sequencing. The American College of Medical Genetics and Genomics (ACMG) retreated in April from its controversial recommendation last year that labs should return incidental findings to the doctor ordering the sequencing for discussion with...
Celgene is using NanoString’s nCounter analysis system to support the clinical validation and development of a companion diagnostic for Revlimid
As recently as ten years ago, just after completion of the Human Genome Project, the concept of a personalized approach to cancer treatment was largely just that—an idea of what could be. And companion diagnostics were limited to predicting patient response to Herceptin for breast cancer and Gleevec for chronic myelogenous leukemia. But it was the introduction of these therapies...

The sixth issue of Clinical OMICs is available now! Check it out by clicking on the link below.

Source: © Alexander Raths - Fotolia.com
Personalized medicine is gaining momentum, but it needs yet more impetus to break into the healthcare mainstream, argues a new report. Released on June 25 by the Personalized Medicine Coalition (PMC), the report examines opportunities for the continued development and adoption of personalized medicine as the cost of genetic sequencing declines, the pharmaceutical industry increases its commitment to personalized...
Source: © Robert Mizerek - Fotolia.com
Cancer Genetics (CGI) said today it plans to acquire Gentris, in an up-to-$6.25 million deal that the buyer said will significantly expand its client base beyond oncology diagnostics, through added capabilities in genomic profiling for clinical trials as well as in pharmacogenomics. “We view this acquisition as part of our long-range strategic plan to deepen our capabilities in developing unique...
Appistry's CSO Richard Mazzarella
The DxMA webcast "Clinically Actionable Genomics: From Sequencing to Personalized Medicine" sponsored by Clinical OMICs is now available for viewing. This webcast focuses on describing the technologies and strategies—such as genome sequencing, massive amounts of genetic data, bioinformatics, and analytics—that are transforming genomic data into clinically actionable intelligence. You will learn: How new gene-based tests have transformed diagnosis, prognostication, risk assessment, and...
Horizon Discovery and LGC have been offered a research grant of £360,224 ($608,000) by the Technology Strategy Board, the U.K.’s innovation agency. The grant is awarded under the board’s collaborative research and development project "Improving Cell and Tissue Analysis for Stratified Medicine" and will fund a joint project run by the company’s Horizon Diagnostics division in partnership with LGC....
Scroll Up